Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by DrHolidayon Jul 13, 2018 2:14pm
150 Views
Post# 28313682

Clarification

ClarificationAfter much reflection, it is my belief that juansito may have bought his shares in ICO based upon a recomendation from his Desjardins broker who has justly earned a commission as the client has been rewarded for making the investment and listening to them. Their research department must be bullish on iCO and there is nothing wrong with prudently taking some profits along the way in order to manage your portfolio by recouping the original investment and even more than that.

No, they are not headhunters that would boil you in a pot, or injuns that would scalp you, just good people working and trying to do the best possible job for all their clients regardless of the size of the account. There is no favoritism and all clients are treated equally. My attempt at humour has been misconstrued and taken out of context, since it was never my intention to mischaracterize or tarnish anyone's reputation unless they have resorted to deception, lies, skullduggery or malfeasance which they have not. You should hire, not fire a good broker like this.

The notion of "scalping" is a euphemism for profit taking on strength and this word is offensive as it denigrates good inidgenous cultures, and if you study your history I think you may find that white men were guilty of this crime in their conquest of North America. So, no more jokes as this appears to be a rather sensitive topic and I wish to offend no one.
Please accept my humble apology, and good luck to all ICO longs and the brokers at Desjardins.

DOC.
<< Previous
Bullboard Posts
Next >>